Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Mar;84(5):704–708. doi: 10.1054/bjoc.2000.1626

A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families

P Vahteristo 1, H Eerola 1,2, A Tamminen 1, C Blomqvist 2,3, H Nevanlinna 1
PMCID: PMC2363799  PMID: 11237395

Abstract

Germline mutations in BRCA1 and BRCA2 genes predispose to hereditary breast and ovarian cancer. Our aim was to find associations between the clinical characteristics and positive mutation status in 148 breast cancer families in order to predict the probability of finding a BRCA mutation in a family. Several factors were associated with mutations in univariate analysis, whereas in multivariate analysis (logistic regression with backward selection) only the age of the youngest breast cancer patient and the number of ovarian cancer cases in a family were independent predictors of BRCA mutations. A logistic model was devised to estimate the probability for a family of harbouring a mutation in either BRCA1 or BRCA2. Altogether, 63 out of 148 families (43%) and 28 out of 29 (97%) mutation carrier families obtained probabilities over 10%. The mean probability was 55% for mutation-positive families and 11% for mutation-negative families. The models by Couch et al (1997) and Shattuck-Eidens et al (1997) previously designed for BRCA1 were also tested for their applicability to distinguish carrier families with mutations in either gene. The probability model should be a useful tool in genetic counselling and focusing the mutation analyses, and thus increasing also the cost-effectiveness of the genetic screening. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: breast cancer, ovarian cancer, BRCA1, BRCA 2, mutation, probability model

Full Text

The Full Text of this article is available as a PDF (58.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berry D. A., Parmigiani G., Sanchez J., Schildkraut J., Winer E. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst. 1997 Feb 5;89(3):227–238. doi: 10.1093/jnci/89.3.227. [DOI] [PubMed] [Google Scholar]
  2. Chang-Claude J., Becher H., Caligo M., Eccles D., Evans G., Haites N., Hodgson S., Møller P., Weber B. H., Stoppa-Lyonnet D. Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes. EC Demonstration Project on Familial Breast Cancer. Dis Markers. 1999 Oct;15(1-3):53–65. doi: 10.1155/1999/238375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Couch F. J., DeShano M. L., Blackwood M. A., Calzone K., Stopfer J., Campeau L., Ganguly A., Rebbeck T., Weber B. L. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med. 1997 May 15;336(20):1409–1415. doi: 10.1056/NEJM199705153362002. [DOI] [PubMed] [Google Scholar]
  4. Eerola H., Blomqvist C., Pukkala E., Pyrhönen S., Nevanlinna H. Familial breast cancer in southern Finland: how prevalent are breast cancer families and can we trust the family history reported by patients? Eur J Cancer. 2000 Jun;36(9):1143–1148. doi: 10.1016/s0959-8049(00)00093-9. [DOI] [PubMed] [Google Scholar]
  5. Fodor F. H., Weston A., Bleiweiss I. J., McCurdy L. D., Walsh M. M., Tartter P. I., Brower S. T., Eng C. M. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet. 1998 Jul;63(1):45–51. doi: 10.1086/301903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Ford D., Easton D. F., Stratton M., Narod S., Goldgar D., Devilee P., Bishop D. T., Weber B., Lenoir G., Chang-Claude J. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998 Mar;62(3):676–689. doi: 10.1086/301749. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Foulkes W. D., Brunet J. S., Warner E., Goodwin P. J., Meschino W., Narod S. A., Goss P. E., Glendon G. The importance of a family history of breast cancer in predicting the presence of a BRCA mutation. Am J Hum Genet. 1999 Dec;65(6):1776–1779. doi: 10.1086/302675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Friedman L. S., Szabo C. I., Ostermeyer E. A., Dowd P., Butler L., Park T., Lee M. K., Goode E. L., Rowell S. E., King M. C. Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families. Am J Hum Genet. 1995 Dec;57(6):1284–1297. [PMC free article] [PubMed] [Google Scholar]
  9. Gayther S. A., Mangion J., Russell P., Seal S., Barfoot R., Ponder B. A., Stratton M. R., Easton D. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet. 1997 Jan;15(1):103–105. doi: 10.1038/ng0197-103. [DOI] [PubMed] [Google Scholar]
  10. Goelen G., Teugels E., Bonduelle M., Neyns B., De Grève J. High frequency of BRCA1/2 germline mutations in 42 Belgian families with a small number of symptomatic subjects. J Med Genet. 1999 Apr;36(4):304–308. [PMC free article] [PubMed] [Google Scholar]
  11. Hodgson S. V., Heap E., Cameron J., Ellis D., Mathew C. G., Eeles R. A., Solomon E., Lewis C. M. Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer. J Med Genet. 1999 May;36(5):369–373. [PMC free article] [PubMed] [Google Scholar]
  12. Hogervorst F. B., Cornelis R. S., Bout M., van Vliet M., Oosterwijk J. C., Olmer R., Bakker B., Klijn J. G., Vasen H. F., Meijers-Heijboer H. Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet. 1995 Jun;10(2):208–212. doi: 10.1038/ng0695-208. [DOI] [PubMed] [Google Scholar]
  13. Hopper J. L., Jenkins M. A. Modeling the probability that Ashkenazi Jewish women carry a founder mutation in BRCA1 or BRCA2. Am J Hum Genet. 1999 Dec;65(6):1771–1776. doi: 10.1086/302674. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hopper J. L., Southey M. C., Dite G. S., Jolley D. J., Giles G. G., McCredie M. R., Easton D. F., Venter D. J. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev. 1999 Sep;8(9):741–747. [PubMed] [Google Scholar]
  15. Huusko P., Päkkönen K., Launonen V., Pöyhönen M., Blanco G., Kauppila A., Puistola U., Kiviniemi H., Kujala M., Leisti J. Evidence of founder mutations in Finnish BRCA1 and BRCA2 families. Am J Hum Genet. 1998 Jun;62(6):1544–1548. doi: 10.1086/301880. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Håkansson S., Johannsson O., Johansson U., Sellberg G., Loman N., Gerdes A. M., Holmberg E., Dahl N., Pandis N., Kristoffersson U. Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer. Am J Hum Genet. 1997 May;60(5):1068–1078. [PMC free article] [PubMed] [Google Scholar]
  17. Kainu T., Juo S. H., Desper R., Schaffer A. A., Gillanders E., Rozenblum E., Freas-Lutz D., Weaver D., Stephan D., Bailey-Wilson J. Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9603–9608. doi: 10.1073/pnas.97.17.9603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Ligtenberg M. J., Hogervorst F. B., Willems H. W., Arts P. J., Brink G., Hageman S., Bosgoed E. A., Van der Looij E., Rookus M. A., Devilee P. Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2. Br J Cancer. 1999 Mar;79(9-10):1475–1478. doi: 10.1038/sj.bjc.6690235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Malone K. E., Daling J. R., Thompson J. D., O'Brien C. A., Francisco L. V., Ostrander E. A. BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history. JAMA. 1998 Mar 25;279(12):922–929. doi: 10.1001/jama.279.12.922. [DOI] [PubMed] [Google Scholar]
  20. Parmigiani G., Berry D., Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet. 1998 Jan;62(1):145–158. doi: 10.1086/301670. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Peelen T., van Vliet M., Petrij-Bosch A., Mieremet R., Szabo C., van den Ouweland A. M., Hogervorst F., Brohet R., Ligtenberg M. J., Teugels E. A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am J Hum Genet. 1997 May;60(5):1041–1049. [PMC free article] [PubMed] [Google Scholar]
  22. Peto J., Collins N., Barfoot R., Seal S., Warren W., Rahman N., Easton D. F., Evans C., Deacon J., Stratton M. R. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst. 1999 Jun 2;91(11):943–949. doi: 10.1093/jnci/91.11.943. [DOI] [PubMed] [Google Scholar]
  23. Rebbeck T. R., Couch F. J., Kant J., Calzone K., DeShano M., Peng Y., Chen K., Garber J. E., Weber B. L. Genetic heterogeneity in hereditary breast cancer: role of BRCA1 and BRCA2. Am J Hum Genet. 1996 Sep;59(3):547–553. [PMC free article] [PubMed] [Google Scholar]
  24. Sarantaus L., Huusko P., Eerola H., Launonen V., Vehmanen P., Rapakko K., Gillanders E., Syrjäkoski K., Kainu T., Vahteristo P. Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland. Eur J Hum Genet. 2000 Oct;8(10):757–763. doi: 10.1038/sj.ejhg.5200529. [DOI] [PubMed] [Google Scholar]
  25. Serova O. M., Mazoyer S., Puget N., Dubois V., Tonin P., Shugart Y. Y., Goldgar D., Narod S. A., Lynch H. T., Lenoir G. M. Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes? Am J Hum Genet. 1997 Mar;60(3):486–495. [PMC free article] [PubMed] [Google Scholar]
  26. Shattuck-Eidens D., Oliphant A., McClure M., McBride C., Gupte J., Rubano T., Pruss D., Tavtigian S. V., Teng D. H., Adey N. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA. 1997 Oct 15;278(15):1242–1250. [PubMed] [Google Scholar]
  27. Struewing J. P., Hartge P., Wacholder S., Baker S. M., Berlin M., McAdams M., Timmerman M. M., Brody L. C., Tucker M. A. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997 May 15;336(20):1401–1408. doi: 10.1056/NEJM199705153362001. [DOI] [PubMed] [Google Scholar]
  28. Syrjäkoski K., Vahteristo P., Eerola H., Tamminen A., Kivinummi K., Sarantaus L., Holli K., Blomqvist C., Kallioniemi O. P., Kainu T. Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst. 2000 Sep 20;92(18):1529–1531. doi: 10.1093/jnci/92.18.1529. [DOI] [PubMed] [Google Scholar]
  29. Szabo C. I., King M. C. Population genetics of BRCA1 and BRCA2. Am J Hum Genet. 1997 May;60(5):1013–1020. [PMC free article] [PubMed] [Google Scholar]
  30. Thorlacius S., Struewing J. P., Hartge P., Olafsdottir G. H., Sigvaldason H., Tryggvadottir L., Wacholder S., Tulinius H., Eyfjörd J. E. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet. 1998 Oct 24;352(9137):1337–1339. doi: 10.1016/s0140-6736(98)03300-5. [DOI] [PubMed] [Google Scholar]
  31. Vehmanen P., Friedman L. S., Eerola H., McClure M., Ward B., Sarantaus L., Kainu T., Syrjäkoski K., Pyrhönen S., Kallioniemi O. P. Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Hum Mol Genet. 1997 Dec;6(13):2309–2315. doi: 10.1093/hmg/6.13.2309. [DOI] [PubMed] [Google Scholar]
  32. Vehmanen P., Friedman L. S., Eerola H., Sarantaus L., Pyrhönen S., Ponder B. A., Muhonen T., Nevanlinna H. A low proportion of BRCA2 mutations in Finnish breast cancer families. Am J Hum Genet. 1997 May;60(5):1050–1058. [PMC free article] [PubMed] [Google Scholar]
  33. Warner E., Foulkes W., Goodwin P., Meschino W., Blondal J., Paterson C., Ozcelik H., Goss P., Allingham-Hawkins D., Hamel N. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst. 1999 Jul 21;91(14):1241–1247. doi: 10.1093/jnci/91.14.1241. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES